Literature DB >> 16274769

Retrospective investigation of hospitalised patients with atrial fibrillation in mainland China.

Q I Wen-Hang1.   

Abstract

OBJECTIVE: To evaluate the epidemiology and status of atrial fibrillation in China.
METHODS: Retrospective analysis of hospital records of patients with a primary diagnosis of atrial fibrillation, discharged between January 1999 and December 2001.
RESULTS: Data were analysed from 9297 patients (mean age 65.5 years) from 41 hospitals in mainland China. During the period studied, atrial fibrillation admissions (mean 7.9%) increased as a proportion of cardiovascular admissions. The distribution of atrial fibrillation increased with age. Causes and associated conditions were advanced age (58.1%), hypertension (40.3%), coronary heart disease (34.8%), heart failure (33.1%), rheumatic valvular disease (23.9%), idiopathic atrial fibrillation (7.4%), cardiomyopathy (5.4%) and diabetes (4.1%). Permanent atrial fibrillation accounted for almost half of the patients (49.5%), and paroxysmal and persistent atrial fibrillation the remainder (33.7% and 16.7%, respectively). Paroxysmal atrial fibrillation was treated mainly by rhythm control (56.4%). In 82.8% of patients with chronic atrial fibrillation, a rate-control strategy was used. The prevalence of stroke was 17.5%. In non-valvular atrial fibrillation, risk factors associated with stroke included advanced age, history of hypertension, coronary heart disease and type of atrial fibrillation. A total of 64.5% of patients received antithrombotic therapy, predominantly with antiplatelet agents. Patients managed with antiplatelet or anticoagulant drugs had a significantly lower stroke rate than those receiving neither treatment, but there was no significant difference between antiplatelet and anticoagulant agents.
CONCLUSION: Most of the atrial fibrillation-related epidemiological factors in this population were similar to those reported in other countries. Antiplatelet and anticoagulant treatment both reduced stroke rate significantly.

Entities:  

Mesh:

Year:  2005        PMID: 16274769     DOI: 10.1016/j.ijcard.2004.12.042

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

Review 1.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

2.  Predictors of incident atrial fibrillation and influence of medications: a retrospective case-control study.

Authors:  James A Hodgkinson; Clare J Taylor; F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

3.  Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus--single center experience.

Authors:  Ri Bo Tang; Jian Zeng Dong; Xing Peng Liu; Dong Ping Fang; De Yong Long; Xiao Hui Liu; Rong Hui Yu; Fu Li Hu; Chun Shan Lu; Peng Hao; Jérôme Kalifa; Chang Sheng Ma
Journal:  J Interv Card Electrophysiol       Date:  2007-01-18       Impact factor: 1.900

4.  Clinical analysis of antithrombotic treatment and occurrence of stroke in elderly patients with nonvalvular persistent atrial fibrillation.

Authors:  Lu-Jiao Yu; Shuai Chen; Yao Xu; Zi-Xin Zhang
Journal:  Clin Cardiol       Date:  2018-10-16       Impact factor: 2.882

5.  Predictors of stroke risk in native Chinese with nonrheumatic atrial fibrillation: retrospective investigation of hospitalized patients.

Authors:  Yihong Sun; Dayi Hu; Kuibao Li; Ziqiang Zhou
Journal:  Clin Cardiol       Date:  2009-02       Impact factor: 2.882

Review 6.  Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?

Authors:  Yutao Guo; Qiang Wu; Lu Zhang; Tingshu Yang; Ping Zhu; Wenqian Gao; Yuexiang Zhao; Meng Gao
Journal:  Clin Interv Aging       Date:  2010-05-25       Impact factor: 4.458

7.  Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.

Authors:  Albert Yuh-Jer Shen; Wansu Chen; Janis F Yao; Somjot S Brar; Xunzhang Wang; Alan S Go
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  The Optimal Treatment For Atrial Fibrillation In Less Developed Countries.

Authors:  Xiaohan Fan; Shu Zhang
Journal:  J Atr Fibrillation       Date:  2014-10-31

9.  Medical treatment and long-term outcome of chronic atrial fibrillation in the aged with chest distress: a retrospective analysis versus sinus rhythm.

Authors:  Yutao Guo; Lu Zhang; Chunjiang Wang; Yuexiang Zhao; Weiren Chen; Meng Gao; Ping Zhu; Tingshu Yang; Yutang Wang
Journal:  Clin Interv Aging       Date:  2011-07-07       Impact factor: 4.458

Review 10.  Shensongyangxin Capsules for Paroxysmal Atrial Fibrillation: A Systematic Review of Randomized Clinical Trials.

Authors:  Guang Chen; Benjun Wei; Jie Wang; Bo Feng; Zhaoling Li; Zhenpeng Zhang; Qingyong He
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.